Molecular Devices’ Post

The future of cell culture and human-relevant screening is here. You will not want to miss this #SLAS2024 talk with Oksana Sirenko of Molecular Devices on their revolutionary new CellXpress.ai Automated Cell culture system. See more: #DanaherLifeSciences #organoids #CellXpress.ai #3DBiology #AIML

SAECs (small airway epithelial cells) are a crucial model for target identification and validation in drug discovery. We have put together a short summary of an automated arrayed CRISPR screen workflow for SAECs with the use of RNPs (for further details see Dickson et al.), 384-well Nucleofector® System and P3 Primary Cell 384-well Nucleofector® Kit.    https://lnkd.in/gSzNMxMc    #nucleofection #screening #CRISPR #automation 

“abcam’s commitment to help accelerate breakthroughs in life science started with antibodies.” Read on to find out how abcam can help to accelerate your drug discovery and development workflow. #DanaherLifeSciences #ELISA #antibodies

Assessment of mitochondrial dysfunction is a big concern in successful drug development campaigns. Check out this study that developed machine-learning models to predict mitochondrial toxicity and found that incorporating data from morphological profiling through Cell Painting created better models. https://hubs.ly/Q02p0Scr0 Get in touch if you want to talk about how we can use cell painting to accelerate your research! #CellPainting #HCS #DrugDiscovery

A key decision when considering #analyticaltestingmethods for #biotherapeutics is whether to pursue an in-house #assaydevelopment strategy or to adopt a commercial kit. This #infographic distills four illustrative case studies to explain the real-life pitfalls that may be encountered when pursuing an in-house #assay development strategy for #advancedtherapy product characterization. https://buff.ly/4e5ROIp Recently published content that covers the steps and challenges that go into in-house development of a #residualDNAassay in detail, and explores innovative research in this space, includes an #article and an on-demand #webinar Article: https://buff.ly/4deeh4F Webinar : https://buff.ly/4deehlb These are just a few of the resources available on our Characterization & Analytics Hub. The hub explores a new generation of analytical tools designed to meet the specific needs of #viralvector and cell-based therapy production, offering the enhanced speed, sensitivity, and robustness that the industry requires. Once you’ve read your first piece of content, all the rest is available to you open access Access the hub below: https://buff.ly/496Nshd

A key decision when considering #analyticaltestingmethods for #biotherapeutics is whether to pursue an in-house #assaydevelopment strategy or to adopt a commercial kit. This #infographic distills four illustrative case studies to explain the real-life pitfalls that may be encountered when pursuing an in-house #assay development strategy for #advancedtherapy product characterization. https://buff.ly/4e5ROIp Recently published content that covers the steps and challenges that go into in-house development of a #residualDNAassay in detail, and explores innovative research in this space, includes an #article and an on-demand #webinar Article: https://buff.ly/4deeh4F Webinar : https://buff.ly/4deehlb These are just a few of the resources available on our Characterization & Analytics Hub. The hub explores a new generation of analytical tools designed to meet the specific needs of #viralvector and cell-based therapy production, offering the enhanced speed, sensitivity, and robustness that the industry requires. Once you’ve read your first piece of content, all the rest is available to you open access Access the hub below: https://buff.ly/496Nshd

The SeromYx team is excited to announce the release of our new white paper titled, "View from the Fc: Five Rules for #mAb Development Risk Reduction." 💡 What you'll learn: 💠 The importance of comprehensive Fc function profiling 💠 The need for whole molecule screening 💠 The impact of the immune complex and Fc engineering on effector function At SeromYx, we specialize in profiling and measuring Fc-driven effector functions, with expertise in both vaccines and #monoclonalantibodies. Our new paper shares valuable insights and lessons learned that could help mAb developers navigate these challenges more effectively. #antibodytherapeutics 🔗 Link to download: https://lnkd.in/dChggSvp

Time is money in drug discovery. So key question is: “How long until my iPSC’s are assay ready and showing a functional response/signal ?” See answers below!! #cellculture #microfluidics #organoids #organonchip #drugdiscovery #drugdevelopment #biotech #pharma #neuroscience #PNS #mea

Curious about how capillary LC-MS is shaping the future of #DrugDevelopment? There's still time to join our Oct. 17th webinar hosted by Separation Science and discover our Lipidomics Analytical Platform for mRNA LNP Innovation, how LC-MS techniques are advancing studies of organoids and organ-on-chip models, sensitive LC-MS analysis, method validation, and more!

#CARNKproduction for clinical applications using #BaEVlentivirus and the #NKcellengineering platform #Lentiviralvector transduction is a well-established step in producing #CARTcell therapies, but traditional #lentiviral #vectors are not well suited to natural killer (NK) cells and yield poor transduction efficiency. This month, Miltenyi Biotec’s Kunal Patel (Manager, Process Engineering)) will discuss the benefits of a novel lentiviral vector for the transduction of #NKcells and explore how a new and robust cell engineering platform generates highly pure CAR-NK cells with potent #cytotoxic functionality. Attend this webinar to learn about: • How baboon envelope glycoprotein pseudotyped lentiviral vector (BaEV-LV) could yield better NK cell transduction efficiency • The production of highly pure CAR-NK cells with potent cytotoxic functionality • How to implement the CliniMACS Prodigy® NK Cell Engineering platform for CAR-NK manufacturing Register for this upcoming #webinar below: